BioSpace News Archive

Genetown

Cambridge’s Scholar Rock Snags Another $47M to Take on Rare Neuromuscular Disease

The round was led by new investor Invus, with participation of another new investor, Redmile Group.

January 3, 2018
·
2 min read
·
Mark Terry
Biotech Beach

New SoCal Biotech Launches With $55.3M Backed by Novartis, Sanofi and 5AM Ventures

The round was co-led by 5AM Ventures, Kleiner Perkins, Novartis Venture Fund, and Sanofi Ventures.

January 3, 2018
·
2 min read
·
Mark Terry
Genetown

Top Biotech Analyst IDs 2 Winners for 2018

The analyst identified Vertex and Alexion as his top two picks among large cap biotechs in 2018.

January 3, 2018
·
1 min read
Policy

FDA Hails Novartis’ Kisqali a Breakthrough

The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.

January 3, 2018
·
2 min read
·
Alex Keown
Deals

Boas Surgical Just Opened Its 10th Office

The nearly 100-year-old medical-device business manufactures prosthetics and orthotics such as foot inserts and knee braces.

January 3, 2018
·
1 min read
Sansure Biotech Raises $77M in Funding Led by Lilly Asia

Sansure Biotech of Changsha raised $77M in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital.

January 3, 2018
·
1 min read
Business

OvaScience Pinks Slips Nearly 50% of Workforce

OvaScience provided a corporate update that includes initial data from a Phase I trial and news of extensive layoffs.

January 3, 2018
·
2 min read
·
Mark Terry
Business

Sangamo, Pfizer Deepen Relationship With New $162M ALS R&D Pact

Sangamo and Pfizer will use the company’s ZFP-TFs to develop the treatments that are linked to mutations of the C9ORF72 gene, which can cause both ALS and FTLD.

January 3, 2018
·
2 min read
·
Alex Keown
Biotech Bay

Spark’s Blindness-Curing Gene Therapy Comes With a $850,000 Price Tag

The therapy is the first type approved by the FDA that targets a disease caused by mutations in a specific gene.

January 3, 2018
·
3 min read
·
Alex Keown
CMAB Closes $38M Series A Financing Round

The company will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products.

January 3, 2018
·
3 min read